Elwood & Goetz Wealth Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$261K Sell
418
-5
-1% -$3.4K 0.04% 129
2026
Q1
$327K Sell
423
-41
-9% -$31.4K 0.06% 101
2025
Q4
$358K Buy
464
+10
+2% +$6.79K 0.06% 87
2025
Q3
$255K Sell
454
-17
-4% -$9.61K 0.05% 111
2025
Q2
$247K Hold
471
0.05% 101
2025
Q1
$299K Hold
471
0.07% 75
2024
Q4
$336K Sell
471
-21
-4% -$17.6K 0.08% 69
2024
Q3
$517K Buy
+492
New +$548K 0.13% 53

Other funds holding REGN

Elwood & Goetz Wealth Advisory Group's REGN Position: Q2 2026 in Review

Elwood & Goetz Wealth Advisory Group reduced its Regeneron Pharmaceuticals (REGN) stake by 1.2% in Q2 2026, selling an estimated $3.4K and leaving 418 shares worth $261K. The position accounts for 0.04% of the portfolio, ranked #129.

Elwood & Goetz Wealth Advisory Group first reported a position in REGN in Q3 2024 and has held it in 8 quarters since. The position peaked at $517K in Q3 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Elwood & Goetz Wealth Advisory Group held 418 shares of Regeneron Pharmaceuticals worth $261K as of Q2 2026.
  • Elwood & Goetz Wealth Advisory Group sold 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4K.
  • Regeneron Pharmaceuticals made up 0.04% of Elwood & Goetz Wealth Advisory Group's portfolio in Q2 2026, its #129 holding.
  • Elwood & Goetz Wealth Advisory Group first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Elwood & Goetz Wealth Advisory Group's Regeneron Pharmaceuticals position peaked at $517K in Q3 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Elwood & Goetz Wealth Advisory Group's 13F filing for Q2 2026, filed 13 Aug 2026.